UroGen Pharma (NASDAQ:URGN) Earns Buy Rating from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma (NASDAQ:URGN) in a research report released on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $31.00 price target on the stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $39.20.

UroGen Pharma Stock Performance

Shares of URGN opened at $10.82 on Wednesday. The company’s 50 day simple moving average is $10.76 and its 200-day simple moving average is $12.22. The firm has a market cap of $253.73 million, a PE ratio of -3.43 and a beta of 1.08. UroGen Pharma has a 12-month low of $9.78 and a 12-month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

Insider Transactions at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Large investors have recently modified their holdings of the business. Barclays PLC grew its holdings in UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after acquiring an additional 48,040 shares during the period. JPMorgan Chase & Co. boosted its position in shares of UroGen Pharma by 263.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after purchasing an additional 49,318 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of UroGen Pharma by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock worth $5,787,000 after purchasing an additional 34,248 shares during the period. Vestal Point Capital LP purchased a new position in shares of UroGen Pharma in the 3rd quarter valued at about $5,080,000. Finally, Rice Hall James & Associates LLC lifted its stake in shares of UroGen Pharma by 273.6% in the third quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company’s stock valued at $3,453,000 after purchasing an additional 199,110 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.